Additional information
| Active substance | Silodosin |
|---|---|
| Formula | C25H32F3N3O4 |
| Side effects | Dizziness, orthostatic hypotension, retrograde ejaculation, headache, diarrhea |
| Effects | Improves urinary flow and symptoms associated with benign prostatic hyperplasia (BPH) |
| Dosage (sports) | Not applicable |
| Dosage (medical) | Typically 8 mg once daily |
| Half-life | Approximately 13 hours |
| Main action | Reduces smooth muscle contraction in the prostate and urethra |
| Substance class | Alpha-1 adrenergic receptor antagonist |
| Chemical name | 1-(3-Hydroxypropyl)-5-[(2R)-2-({2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl}amino)propyl]-2,3-dihydro-1H-indole-7-carboxamide |
| Storage conditions | Store at room temperature, away from moisture and heat |
| Trade name | Rapaflo, Silodyx |
| Blood pressure | May cause a decrease in blood pressure |
| Also known as | KMD-3213 |
| Lab Test | Not specific |
| Hepatotoxicity | Low |
| Water Retention | Minimal to none |
| Use in sports | None |
| Manufacturer | Recordati |
| Packing | 30 tabs (4mg/tab) |
Reviews
There are no reviews yet.